依巴斯汀联合雷尼替丁在慢性荨麻疹中的综合疗效
 |
| 第1页 |
参见附件(2144KB，2页)。
[摘要] 目的：探讨依巴斯汀联合雷尼替丁在慢性荨麻疹中的综合疗效。方法：选取2008年6月~2010年11月于本院进行治疗的86例慢性荨麻疹患者为研究对象，将其随机分为对照组(西替利嗪联合雷尼替丁组)43例和观察组(依巴斯汀联合雷尼替丁组)43例，后将两组患者的治疗总有效率、不良反应发生率及治疗前后的血清总IgE、HA、ECP、5-HT、LT水平进行统计及比较。结果：观察组的治疗总有效率高于对照组，不良反应发生率低于对照组，血清总IgE、HA、ECP、LT水平低于对照组，血清5-HT高于对照组，P<0.05或P<0.01，差异有统计学意义或显著统计学意义。结论：依巴斯汀联合雷尼替丁在慢性荨麻疹中的综合疗效较佳，可影响血清总IgE、HA、ECP、5-HT、LT水平，可以作为治疗慢性荨麻疹的方案。
[关键词] 依巴斯汀；雷尼替丁；慢性荨麻疹；疗效
[中图分类号] R758.24[文献标识码]B [文章编号]1674-4721(2011)07(b)-058-02
The comprehensive therapeutic effect of ebastine combined with ranitidine in chronic urticaria
REN Shuhui
Dermatology Department of Bazhong Central Hospital, Sichuan Province, Bazhong 636600, China
[Abstract] Objective: To study the comprehensive therapeutic effect of ebastine combined with ranitidine in chronic urticaria. Methods: 86 patients with chronic urticaria in our hospital from June 2008 to November 2010 were selected as research object, and they were randomly divided into control group (cetirizine combined with ranitidine group) 43 cases and observation group (ebastine combined with ranitidine group) 43 cases, then the total effective rate, incidence of adverse reactions and serum total IgE, HA, ECP, 5-HT, LT of two groups before and after the treatment were analyzed and compared. Results: The total effective rate of observation group was higher than that of control group, incidence of adverse reactions was lower than that of control group, serum total IgE, HA, ECP, serumLT were lower, 5-HT was higher, P<0.05 or P<0.01, there were significant or very significant differences. Conclusion: The comprehensive therapeutic effect of ebastine combined with ranitidine in chronic urticaria. It can influence theserum total IgE, HA, ECP, 5-HT, LT and it can be the therapeutic scheme of chronic urticaria.
[Key words] Ebastine combined; Ranitidine; Chronic urticaria; Effects
慢性荨麻疹属自身免疫机制参与的过敏性皮肤疾病，发病机制为机体所产生自身抗体引发嗜碱粒细胞脱颗粒，导致组胺释放和皮肤病变，病因较多[1]。本病治疗方案较多，综合效果方面差异却较大。本文中笔者就依巴斯汀联合雷尼替丁在慢性荨麻疹中的综合疗效进行观察，现报道如下：
1 资料与方法
1.1 一般资料
选取2008年6月~2010年11月于本院进行治疗的86例慢性荨麻疹患者为研究对象，将其随机分为对照组(西替利嗪联合雷尼替丁组)43例和观察组(依巴斯汀联合雷尼替丁组)43例 ......
您现在查看是摘要介绍页，详见PDF附件(2144KB，2页)。